Načítá se...
Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a number of EGFR-targeted agents have been developed. Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib (‘Iressa’, ZD1839) and erlotinib (‘Tarceva’, OSI-774), and the monoclona...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2004
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2409596/ https://ncbi.nlm.nih.gov/pubmed/14760365 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601550 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|